Thank you, Brian, and welcome, everyone. We are pleased to discuss our results for the full year 2023 and recent activity as we enter into our eighth full year of operations. The company performed well in 2023 and has continued to execute year-to-date, demonstrated by one, annual AFFO per share growth of 7%. Two, increasing our annual dividends declared each year since inception in 2016; three, committing capital totaling $119.5 million during 2023. Four, executing new leases and LOIs to release five properties, representing over $140 million of invested capital and five, further enhancing our liquidity position and strong balance sheet with the closing of a new $45 million revolving credit facility. For the year, IIP generated total revenues of $310 million and adjusted funds from operations of $256 million, increases of 12% and 10% over 2022, respectively. I would note that these growth results were achieved during a time when we strategically determined to reduce our investigate increase cost of capital. That financial performance allowed us to continue to grow our dividend. With $7.22 of common stock dividends declared over the course of 2023. Annual dividends increasing each year since inception. Our most recent dividend declared in Q4 of $1.82 per share was at the midpoint of our Board's target dividend payout range of 75% to 85% of AFFO. We have one of the strongest and most experienced teams of real estate professionals in the cannabis industry, a high-quality portfolio and a conservative and flexible balance sheet with a 12% debt to total gross assets. No variable rate debt, no debt maturities until May 2026. We further enhanced our balance sheet position during Q4 with introduction of a revolving credit facility and then recently upsized that facility earlier this month, which David will touch on further. On the investments front, we are very pleased with our execution on releasing initiatives as well as the opportunities we are seeing to selectively close on new investments, which Ben will discuss in more detail. From a regulatory perspective, as we noted in our prior call, we continue to follow closely the potential rescheduling of cannabis from Schedule 1 to Schedule 3 under the Controlled Substance Act. Of course, there are significant benefits to this, the most important of which, from our perspective, is the potential lifting of the confiscatory 280e federal taxes imposed on regulated cannabis operators, and Paul will discuss our thoughts in more detail. I will now turn the call over to Paul to discuss licensing, regulatory and industry dynamics. Paul?